CD8A and neoplasm: After sequencing and analyzing malignant and healthy cells by whole exome sequencing, Ott’s team designed a vaccine of up to 20 predicted individual tumor neoantigens—“NeoVax”—that induced multifunctional CD4+ and CD8+ T cells to target 58 (60%) and 15 (16%) of the 97 novel neoantigens found in tumor patients, respectively.